NEW YORK (GenomeWeb) – Molecular diagnostics firm OpGen has priced a private placement in which it hopes to raise $10.4 million.

The Gaithersburg, Maryland-based firm will issue 9,053,556 units at a price of $1.14375 each, consisting of one share of common stock and a warrant to purchase three quarters of one share. The five-year warrants will be exercisable 90 days after the placement closes, with an exercise price of $1.3125 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.